ReviewTrends in parasitology2021
High-content approaches to anthelmintic drug screening.
Review in Trends in parasitology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs.PLoS pathogens · 2026Article
- Nematicidal indole oxazoles and chemoattractants from soil bacteria.bioRxiv : the preprint server for biology · 2026Article
- Pelodera: cosmopolitan phoretic saprotrophs and neglected models for origins of nematode parasitism.Parasites & vectors · 2025Review
- Drug screens using the nematode Caenorhabditis elegans.Genetics · 2025Review
- A graphical user interface for wrmXpress 2.0 streamlines helminth phenotypic screening.International journal for parasitology. Drugs and drug resistance · 2025Article
- Article
- Machine learning prediction of multiple anthelmintic resistance and gastrointestinal nematode control in sheep flocks.Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria · 2024Article
- Quantifying metabolic activity of Ascaris suum L3 using resazurin reduction.Parasites & vectors · 2023Article
- A high-throughput sensory assay for parasitic and free-living nematodes.Integrative biology : quantitative biosciences from nano to macro · 2023Article
- Phenotypic Profiling of Macrocyclic Lactones on ParasiticAntimicrobial agents and chemotherapy · 2023Article
- Pharmacological Profiling of a Brugia malayi Muscarinic Acetylcholine Receptor as a Putative Antiparasitic Target.Antimicrobial agents and chemotherapy · 2023Article
- Current Landscape of Methods to Evaluate Antimicrobial Activity of Natural Extracts.Molecules (Basel, Switzerland) · 2023Review
- Multivariate chemogenomic screening prioritizes new macrofilaricidal leads.Communications biology · 2023Article
- wrmXpress: A modular package for high-throughput image analysis of parasitic and free-living worms.PLoS neglected tropical diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Most anthelmintics were discovered through in vivo screens using animal models of infection. Developing in vitro assays for parasitic worms presents several challenges. The lack of in vitro life cycle culture protocols requires harvesting worms from vertebrate hosts or vectors, limiting assay throughput. Once worms are removed from the host environment, established anthelmintics often show no obvious phenotype - raising concerns about the predictive value of many in vitro assays. However, with recent progress in understanding how anthelmintics subvert host-parasite interactions, and breakthroughs in high-content imaging and machine learning, in vitro assays have the potential to discern subtle cryptic parasite phenotypes. These may prove better endpoints than conventional in vitro viability assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.